Americans Sick Of Meds That Don’t Restore Health Love The Idea Of RFK Leading HHS

It baffles me that people find America's abysmal health statistics less shocking than the appointment of RFK Jr.

Big Pharma And Big Food Are Shaking In Their Boots At A Second Trump Era

The incoming Trump administration poses a major threat to the unholy alliance between pharmaceutical giants and Big Agriculture.

ROOKE: Republicans Are Winning A War The Left Started

They are no longer the side that cares about our health and safety

Lawmakers: Big Pharma Might Be Cashing In On Experiments On Chinese Slaves

U.S. companies 'could be unintentionally profiting from the data derived from clinical trials during which the CCP forced victim patients to participate.'

Use of ADHD drugs surged during pandemic, fueling shortages: Study



Prescriptions for medications to treat attention-deficit/hyperactivity disorder, or ADHD, surged during the COVID-19 pandemic, according to a new study.

Prescriptions for stimulant and non-stimulant ADHD medications spiked during the coronavirus pandemic, according to a new study published in JAMA Psychiatry on Wednesday. The sudden demand for ADHD drugs helped fuel a shortage.

There were approximately 5.9 million new prescriptions for stimulants in the first two years of the coronavirus pandemic — roughly 700,000 more than in the two years before the pandemic started, or a 14% increase. Non-stimulant ADHD drug-use soared by 32% during the pandemic.

Stimulant prescriptions for American adults ages 20 to 39 flared up 30% compared to before the pandemic. Meanwhile, non-stimulant ADHD prescriptions for the same age group skyrocketed by 81%.

The use of stimulants and non-stimulant ADHD drugs rose by 25% in women.

Meanwhile, prescriptions for other behavioral health issues — including antidepressants, benzodiazepines, and buprenorphine — did not change significantly in that same time period.

Dr. Ann Childress told Time magazine that the increase in ADHD medication usage is likely due to more people working from home and getting easily distracted.

The Las Vegas-based psychiatrist added, “People are more open to talking about mental health issues now."

Telemedicine also increased ADHD medication use because it made it easier to get the medications.

In October, the Drug Enforcement Administration and the Department of Health and Human Services announced it had extended telemedicine flexibilities through Dec. 31, 2024.

Another possible factor was people becoming more aware of adult ADHD on social media.

A study from the Centers for Disease Control and Prevention released in March also found that ADHD drug use increased during the COVID-19 pandemic. The CDC said stimulant prescriptions rose from 3.6% in 2016 to 4.1% in 2021. However, stimulant prescriptions rose more than 10% for females aged 15-44 years and males aged 25-44 years during 2020-2021.

There was previously a "demand-driven" shortage of Adderall — a common stimulant used to treat ADHD.

In October 2022, the Food and Drug Administration announced a shortage of the "immediate-release formulation of amphetamine mixed salts, commonly referred to by the brand name Adderall or Adderall IR."

An FDA spokesperson told ABC News on Thursday that some manufacturers of ADHD medications are still having "supply issues," but there are currently nine manufacturers with availability. The spokesperson added that "there will be additional supply returning in the coming months."

The DEA and FDA previously called on manufacturers to increase production to meet the elevated demand.

Adderall production is limited by the DEA because it is a controlled substance.

The Mayo Clinic defines attention-deficit/hyperactivity disorder as a "chronic condition that affects millions of children and often continues into adulthood" that "includes a combination of persistent problems, such as difficulty sustaining attention, hyperactivity, and impulsive behavior."

The CDC estimates that there are approximately 6 million children between the ages of 3 and 17 — about 10% — who have been diagnosed with ADHD.

Like Blaze News? Bypass the censors, sign up for our newsletters, and get stories like this direct to your inbox. Sign up here!

How Democrats’ Prescription Price Controls Are Making Americans Sick

The 60,000 patients diagnosed with ovarian cancer over the next three years could be out of luck for a treatment, thanks to Biden and congressional Democrats.

Exclusive: Texas AG Ken Paxton Sues Pfizer For ‘False, Deceptive’ Covid Jab Con

The lawsuit alleges Pfizer ‘engaged in false, deceptive, and misleading acts and practices by making unsupported claims’ about its Covid jab.

CDC says just 2% of Americans received new COVID vaccine. Pfizer undergoes $3.5 billion in cost-cutting measures as sales for COVID-19 products plummet.



Only 2% of Americans have gotten the updated COVID-19 vaccine, according to the Centers for Disease Control and Prevention.

The updated COVID vaccine created to provide more protection against current coronavirus variants circulating was approved by the U.S. Food and Drug Administration on Sept. 11, 2023.

"The approval of Comirnaty (COVID-19 Vaccine, mRNA) (2023-2024 Formula) was granted to BioNTech Manufacturing GmbH. The EUA amendment for the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) was issued to Pfizer Inc," the FDA stated. "The approval of Spikevax (COVID-19 Vaccine, mRNA) (2023-2024 Formula) was granted to ModernaTX Inc. and the EUA amendment for the Moderna COVID-19 Vaccine (2023-2024 Formula) was issued to ModernaTX Inc."

The next day, the CDC recommended that every U.S. citizen over the age of six months get the updated COVID vaccine manufactured by Moderna and Pfizer-BioNTech.

President Joe Biden added the same day, "I encourage all Americans to stay up-to-date on their vaccines."

The CDC urged, "If you have not received a COVID-19 vaccine in the past 2 months, get an updated COVID-19 vaccine to protect yourself this fall and winter."

Despite the push by the government to get the new shots in the arms of Americans, just about 2% of U.S. citizens have opted to get the new booster vaccine.

The U.S. Department of Health and Human Services revealed that 7 million Americans received the latest updated COVID vaccine – roughly 2% of the United States population.

CNN reported, "In comparison, when last year’s bivalent COVID-19 booster was available, more than 18 million people had received a dose by October 12, 2022, about six weeks after the CDC signed off on it, according to CDC data. By May, about 56.5 million people had received that booster, representing about 17% of the U.S. population."

The vaccination rates for the booster shots are severely lagging compared to previous iterations of the mRNA vaccine aimed at targeting COVID.

According to CDC data, over 92% of U.S. adults received the first COVID vaccine that rolled out in December 2020. Those who got the second mRNA vaccine dropped to 79%, and a mere 20% of Americans received the bivalent COVID booster.

An HHS spokesperson said, "COVID-19 vaccine distribution, which has shifted to the private market, is a lot different than it was last year when the government was distributing them. The Biden-Harris Administration, through HHS, has been working directly with manufacturers and distributors to ensure that the vaccines are getting to pharmacies, hospitals, clinics, pediatricians, and other vaccination sites, including long-term care facilities."

Despite the switch to private distribution, the HHS boasted that pharmacies and other locations have already received nearly 14 million vaccines, and that "91% of Americans 12 years and older can access the vaccine within 5 miles of where they live."

Most Americans can receive a free COVID-19 vaccine through health insurance, local health centers, and pharmacies participating in the CDC's Bridge Access Program.

On Friday, Pfizer announced that the pharmaceutical behemoth would have to cut $3.5 billion in costs due to rapidly deteriorating profits from COVID-19 products.

"Pfizer also announced that it now anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion solely due to its COVID products," the statement read. "Full-year 2023 revenues for Paxlovid and Comirnaty are expected to be approximately $12.5 billion, a decline of $9.0 billion versus original expectations."

Pfizer revealed that has already launched a "multi-year, enterprise-wide cost realignment program that will realign its costs with its longer-term revenue expectations." Pfizer said the cost-cutting measures will save the pharmaceutical company at least $3.5 billion – $1 billion in 2023 and $2.5 billion in 2024.

Like Blaze News? Bypass the censors, sign up for our newsletters, and get stories like this direct to your inbox. Sign up here!

Former White House Coronavirus Task Force adviser Deborah Birx named CEO of pharmaceutical company, has been active in private sector since leaving government positions



Deborah Birx – the former White House Coronavirus Task Force coordinator under former President Donald Trump – has been named as the CEO of a pharmaceutical company.

In a July 11 press release, Armata Pharmaceuticals announced that Birx, 67, would be the new Chief Executive Officer of the biotechnology company.

Robin C. Kramer, Chair of Armata's Board of Directors, said, "On behalf of the Armata Board and leadership, I would like to welcome Dr. Birx to the team. As we continue to work to introduce novel phage therapeutics to combat serious bacterial infections, Deborah's expertise in immunology and infectious diseases together with her proven leadership skills will serve us well. I look forward to her contributions as CEO and a member of our Board."

Birx said of her new CEO position, "I am thrilled to join Armata at this pivotal time in the Company's development. I'm impressed with the scientific platform's quality and the team's commitment to introducing innovative treatment options for patients suffering from serious bacterial infections. I am excited about the recent advances and see multiple opportunities to accelerate the Company's progress and drive value creation. The recent investment enables the advancement of AP‐PA02 and AP‐SA02 in Phase 2 clinical trials."

Armata Pharmaceuticals is a self-described "clinical‐stage biotechnology company focused on the development of pathogen‐specific bacteriophage therapeutics for the treatment of antibiotic‐resistant and difficult‐to‐treat bacterial infections using its proprietary bacteriophage‐based technology."

The California-based pharmaceutical company said it is currently "developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens."

Birx announced her retirement in December 2020 during an interview by saying, "I want the Biden administration to be successful. I've worked since 1980 in the federal government, first through the military, then through [the Department of Health and Human Services], and then detailed to the State Department and detailed here, where I hope I was helpful. I will be helpful in any role people think I can be helpful in, and then I will retire."

Birx left her position as White House Coronavirus Response Coordinator in January 2021, according to a LinkedIn profile.

The same month, she resigned from her position as the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy.

In March 2021, Birx became a Senior Fellow at the George W. Bush Presidential Center, which said: "Deborah L. Birx, M.D., has spent her career serving the United States, first as an Army Colonel and later, running some of the most high-profile and influential programs at the U.S. Centers for Disease Control and Prevention and U.S. Department of State."

In March 2021, Birx joined the board of directors at Innoviva – a self-described "diversified holding company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited (GSK), as well as a growing portfolio of innovative healthcare investments and assets in areas of significant unmet medical need."

Also in March 2021, Birx became a "Medical and Science Advisor" at ActivePure – a technology company with a self-described "commitment to creating the purest indoor space possible."

In September 2022, Birx joined the board of directors for Nanolive – a Swiss microscope company that claims to provide "breakthrough imaging and analysis solutions that accelerate research in growth industries such as drug discovery and cell therapy."

In October 2022, Birx was named a member of the Federal Advisory Board for Palantir – a software company specializing in data analytics and data integration. TechCrunch previously reported, "As of 2013, Palantir was used by at least 12 groups within the US Government including the CIA, DHS, NSA, FBI, the CDC, the Marine Corps, the Air Force, Special Operations Command, West Point, the Joint IED-defeat organization and Allies, the Recovery Accountability and Transparency Board and the National Center for Missing and Exploited Children."

Like Blaze News? Bypass the censors, sign up for our newsletters, and get stories like this direct to your inbox. Sign up here!

Pharma Lawsuit Shows The Extent Of Biden’s Health Care Stranglehold

Merck calls 'negotiation' provisions in Biden's Inflation Reduction Act 'unconstitutional,' but there may be no way out.